Prevalence of Histological Characteristics of Breast Cancer in Rwanda in Relation to Age and Tumor Stages.


Journal

Hormones & cancer
ISSN: 1868-8500
Titre abrégé: Horm Cancer
Pays: United States
ID NLM: 101518427

Informations de publication

Date de publication:
10 2020
Historique:
received: 06 04 2020
accepted: 14 07 2020
pubmed: 11 8 2020
medline: 26 8 2021
entrez: 11 8 2020
Statut: ppublish

Résumé

Breast cancer is a complex disease, and it is the most common cause of morbidity and mortality among women worldwide. In Sub-Saharan Africa, the clinical characteristics and tumor profiles of breast cancer are still unknown. In the present study we aimed to determine breast tumor profiles of the Rwandan patients in relation to age and tumor stages. We compare our findings to related results from other sub-Saharan Africa studies. Data on age at diagnosis, tumor stage, and hormonal profiles of 138 patients diagnosed between January 2015 and December 2018 were retrospectively retrieved from electronic medical records at three referral hospitals in Rwanda. We compared our results to related findings reported in other Sub-Saharan African countries. All statistical analyses were done using SPSS Inc., Chicago, IL, USA, version 20 and R software languages. The mean age at diagnosis was 49.7 years (SD = 13) and ranged from 17 to 86 years. The majority of patients (57.2%) were diagnosed before 50 years of age compared with 42.8% aged > 50 years. Tumor stage III was the commonest accounting for 62% followed by stage II with 24.8%. The distribution of breast tumor subtypes was ER-, PR-, HER2-: 37.7%; ER+, PR+, HER2-: 31.2%; ER-, PR-, HER2+: 14.5%; ER+, PR+, HER2+: 5.1%; and other subtypes represented 11.6%. There was no statistically significant difference in age and tumor stages between the molecular subtypes. Our findings revealed the predominance of hormonal negative tumors among Rwandan patients with breast cancer. Triple negative was found to be the most common breast tumor subtype regardless of age and tumor stage. Larger prospective studies could examine genetics and environmental factors that may play a role in the differences of tumor characteristics in Sub-Saharan populations.

Identifiants

pubmed: 32772262
doi: 10.1007/s12672-020-00393-3
pii: 10.1007/s12672-020-00393-3
pmc: PMC10355233
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

240-249

Références

Pathobiology. 2016;83(1):24-32
pubmed: 26730581
Afr Health Sci. 2009 Dec;9(4):242-6
pubmed: 21503175
BMC Res Notes. 2014 Jun 26;7:399
pubmed: 24964871
Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S8
pubmed: 21172092
Breast Cancer Res Treat. 2009 Jan;113(2):357-70
pubmed: 18324472
BMC Womens Health. 2018 Feb 14;18(1):40
pubmed: 29444670
Breast Cancer Res Treat. 2018 Jul;170(1):111-118
pubmed: 29479644
Arch Public Health. 2011 Oct 24;69(1):2
pubmed: 22958447
J Natl Cancer Inst. 2012 Jul 18;104(14):1094-101
pubmed: 22773826
Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12
pubmed: 23012306
Cancer. 2019 Oct 1;125(19):3401-3411
pubmed: 31190337
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Am J Surg. 2013 Apr;205(4):409-13
pubmed: 23375755
Lancet Oncol. 2010 Feb;11(2):165-73
pubmed: 20005175
Oncol Lett. 2011 Mar;2(2):323-330
pubmed: 22866085
Breast Cancer Res Treat. 2014 Apr;144(3):467-78
pubmed: 24604092
BMC Cancer. 2017 Feb 7;17(1):115
pubmed: 28173783
Breast Cancer Res. 2013;15(5):R84
pubmed: 24041225
Oncology. 2012;83(5):257-63
pubmed: 22964749
Ecancermedicalscience. 2017 Aug 30;11:763
pubmed: 28900476
Int J Cancer. 2020 Aug 1;147(3):709-718
pubmed: 31675126
Breast. 2015 Oct;24(5):642-8
pubmed: 26279132
Breast Cancer Res. 2009;11(2):R18
pubmed: 19320967
Pan Afr Med J. 2019 May 14;33:22
pubmed: 31312338
BMC Cancer. 2014 Feb 04;14:62
pubmed: 24495414
J Clin Invest. 2011 Oct;121(10):3797-803
pubmed: 21965336
J Clin Oncol. 2009 Sep 20;27(27):4515-21
pubmed: 19704069
Breast. 2014 Oct;23(5):591-6
pubmed: 25012047
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
BMC Cancer. 2017 Dec 1;17(1):804
pubmed: 29191181
Cancer Biol Ther. 2010 Nov 15;10(10):955-60
pubmed: 21057215
Nat Rev Cancer. 2014 Dec;14(12):815-21
pubmed: 25355378
Oncologist. 2015 Jul;20(7):780-8
pubmed: 26032138
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Br J Cancer. 2008 Jan 29;98(2):277-81
pubmed: 18182985
World J Clin Oncol. 2014 Aug 10;5(3):412-24
pubmed: 25114856
Pathol Int. 2002 Mar;52(3):186-94
pubmed: 11972862
Breast Care (Basel). 2013 May;8(2):149-54
pubmed: 24415964
BMC Cancer. 2016 Mar 10;16:204
pubmed: 26964534
Pan Afr Med J. 2014 Apr 05;17:249
pubmed: 25309649
Ann Surg Oncol. 2016 Nov;23(12):3843-3849
pubmed: 27469125
Breast. 2013 Oct;22(5):828-35
pubmed: 23489760
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
J Clin Oncol. 2015 Nov 1;33(31):3621-7
pubmed: 26371147
JAMA. 2006 Jun 7;295(21):2492-502
pubmed: 16757721
Breast J. 2009 Nov-Dec;15(6):593-602
pubmed: 19764994
Mod Pathol. 1998 Feb;11(2):155-68
pubmed: 9504686
BMC Cancer. 2018 Apr 5;18(1):387
pubmed: 29621999
Nat Rev Cancer. 2015 Apr;15(4):248-54
pubmed: 25673085
Oncologist. 2016 May;21(5):571-5
pubmed: 27009935

Auteurs

Jeanne P Uyisenga (JP)

College of Science and Technology, University of Rwanda, 4285, Kigali, Rwanda.
Laboratory of Human Genetics, GIGA Research Institute, University of Liege, B34, +2, 4000, Liege, Belgium.

Yvan Butera (Y)

Rwanda Cancer Centre, Rwanda Military Hospital, Kanombe, 4062, Kigali, Rwanda.
Department of Medical Oncology, University Hospital (CHU Liege), B35, 2, 4000, Liege, Belgium.

Ahmed Debit (A)

Laboratory of Human Genetics, GIGA Research Institute, University of Liege, B34, +2, 4000, Liege, Belgium.

Claire Josse (C)

Laboratory of Human Genetics, GIGA Research Institute, University of Liege, B34, +2, 4000, Liege, Belgium.
Department of Medical Oncology, University Hospital (CHU Liege), B35, 2, 4000, Liege, Belgium.
Laboratory of Medical Oncology, GIGA Research Institute, University of Liege, B34, +2, 4000, Liege, Belgium.

Costas C Ainhoa (CC)

Rwanda Cancer Centre, Rwanda Military Hospital, Kanombe, 4062, Kigali, Rwanda.

Emile Karinganire (E)

Rwanda Cancer Centre, Rwanda Military Hospital, Kanombe, 4062, Kigali, Rwanda.

Aimee P Cyuzuzo (AP)

College of Science and Technology, University of Rwanda, 4285, Kigali, Rwanda.

Nicole Umurungi (N)

College of Science and Technology, University of Rwanda, 4285, Kigali, Rwanda.

Yves Kalinijabo (Y)

College of Science and Technology, University of Rwanda, 4285, Kigali, Rwanda.

Simeon Uwimana (S)

Kigali University Teaching Hospital, PO Box 655, Kigali, Rwanda.

Leon Mutesa (L)

Center for Human Genetics, College of Medicine and Health Sciences, University of Rwanda, 4285, Kigali, Rwanda.

Vincent Bours (V)

Laboratory of Human Genetics, GIGA Research Institute, University of Liege, B34, +2, 4000, Liege, Belgium. vbours@uliege.be.
Department of Human Genetics, University of Liege, CHU Liege, Liege, Belgium. vbours@uliege.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH